Order Drugs Now

TEL: 1 866 893 0369
FAX: 1 866 402 4033

Pharma Industry News

Subscribe to Newsletter

To get info on the latest products, specials and pharmacy news, please enter your e-mail address:


August 19th, 2009
FDA Advises of Pure Red Cell Aplasia Found in CellCept Patients

The U.S. FDA and Roche have informed healthcare practitioners that patients being treated with CellCept, have reported cases of Pure Red Cell Aplasia, also known as PRCA.

August 19th, 2009
Gaucher Treatment Drug prGCD Newly Approved

Although, prGCD, a new drug used to treat patients with a unique genetic disorder - Gaucher disease, has not received full market approval, the U.S. FDA has said that physicians may utilize the drug for treatment.

August 17th, 2009
FDA Endorses Multiple Sclerosis Treatment, Extavia

Novartis has recently announced the U.S. FDA approval of their multiple sclerosis treatment drug: Extavia (Interferon beta 1-b). The FDA approved the drug for patients that suffer from a relapse of the auto immune disease, or for those patients whom are newly diagnosed with MS.

August 17th, 2009
DSG’s EDC Enables Human Genome to Achieve Benlysta Drug Objectives

After Benlysta achieved the primary endpoint in Bliss - 52, Human Genome Sciences, is pleased report that the first two pivotal Phase 3 trials involving patients with serologically active systematic lupus erythematous has been completed. The results have began to prove that Benlysta may in fact possess the potential to become the first approved systematic lupus treatment in decades.

August 17th, 2009
Saphris Sublingual Tabs Receives FDA Endorsement

The US FDA has approved Saphris sublingual tablets for the acute therapy of schizophrenic adults, as well as the acute therapy of manic or mixed bipolar I disorder, with or without adult psychotic attributes. Saphris is endorsed for first-line therapy, and is the first prescription drug to receive primary consent for both of these symptoms concurrently.

August 13th, 2009
Top-Line Results From Zelrix Phase III, Clinical Trials

Specialty pharmaceutical company, who specializes in the generation of revolutionary products to treat neurological and psychiatric diseases, publicizes top-line results from the Phase III Zelrix clinical tria

August 13th, 2009
FDA Assists Patients With Access to Investigational Drugs

The U.S. FDA has recently announced two rules that are intended to explicate accessible strategies for critically ill patients who are interested in obtaining access to investigational drugs and biologics.

August 12th, 2009
Canadian Research Team Successfully Reverses Multiple Sclerosis in Mice

A group of Canadian scientists claim to have successfully suppressed the immune system of an experimental group of mice, thereby reversing multiple sclerosis into remission.

August 12th, 2009
University Study Looks to Thiazole Antibiotics to Target Cancer

Scientists continue to unravel a new discovery surrounding a recently approved class of antibiotics and its effect on cancer.

August 11th, 2009
Astella Challenges FDA on Anti-Rejection Medication Testing and Labeling

Astellas Pharma US Inc. has publicized the US Food and Drug’s rejection of the company’s Citizen Petition to secure the safe and valuable use of immunosuppressants.


Search for Medication or Types of Conditions



: 0
Total: $0.00

view my cart check out credit cards

Find out how much you can save now!

download order form


Medicine Shoppe Pharmacy
148 #9 31205 Maclure Road
Abbotsford BC, Canada

Ph: 1-866-893-0369
Fax: 1-800-878-7930

Licence J30
Manager: S. Maan


TEL: 1 (866) 893-0369
FAX: 1 (800) 878-7930